A network meta-analysis on randomized trials focusing on the preventive effect of statins on contrast-induced nephropathy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A network meta-analysis on randomized trials focusing on the preventive effect of statins on contrast-induced nephropathy. / Peruzzi, Mariangela; De Luca, Leonardo; Thomsen, Henrik S; Romagnoli, Enrico; D'Ascenzo, Fabrizio; Mancone, Massimo; Sardella, Gennaro; Lucisano, Luigi; Abbate, Antonio; Frati, Giacomo; Biondi-Zoccai, Giuseppe.
In: Journal of Biomedicine and Biotechnology, Vol. 2014, 2014, p. 1-10.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A network meta-analysis on randomized trials focusing on the preventive effect of statins on contrast-induced nephropathy
AU - Peruzzi, Mariangela
AU - De Luca, Leonardo
AU - Thomsen, Henrik S
AU - Romagnoli, Enrico
AU - D'Ascenzo, Fabrizio
AU - Mancone, Massimo
AU - Sardella, Gennaro
AU - Lucisano, Luigi
AU - Abbate, Antonio
AU - Frati, Giacomo
AU - Biondi-Zoccai, Giuseppe
PY - 2014
Y1 - 2014
N2 - Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive. Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.
AB - Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive. Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.
U2 - 10.1155/2014/213239
DO - 10.1155/2014/213239
M3 - Journal article
C2 - 25276771
VL - 2014
SP - 1
EP - 10
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
ER -
ID: 135227560